Endocrinol Metab.  2014 Dec;29(4):450-456. 10.3803/EnM.2014.29.4.450.

Using Growth Hormone Levels to Detect Macroadenoma in Patients with Acromegaly

Affiliations
  • 1Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • 2Department of Endocrinology and Metabolism, Gachon University Gil Medical Center, Gachon University of Medicine and Science, Incheon, Korea. kwkim@gilhospital.com

Abstract

BACKGROUND
The aim of this study was to assess the clinical differences between acromegalic patients with microadenoma and patients with macroadenoma, and to evaluate the predictive value of growth hormone (GH) levels for early detection of macroadenoma.
METHODS
We performed a retrospective analysis of 215 patients diagnosed with a GH-secreting pituitary adenoma. The patients were divided into two groups: the microadenoma group and the macroadenoma group, and the clinical parameters were compared between these two groups. The most sensitive and specific GH values for predicting macroadenoma were selected using receiver operating characteristic (ROC) curves.
RESULTS
Compared with the microadenoma group, the macroadenoma group had a significantly younger age, higher body mass index, higher prevalence of hyperprolactinemia and hypogonadism, and a lower proportion of positive suppression to octreotide. However, there were no significant differences in the gender or in the prevalence of diabetes between the two groups. The tumor diameter was positively correlated with all GH values during the oral glucose tolerance test (OGTT). All GH values were significantly higher in the macroadenoma group than the microadenoma group. Cut-off values for GH levels at 0, 30, 60, 90, and 120 minutes for optimal discrimination between macroadenoma and microadenoma were 5.6, 5.7, 6.3, 6.0, and 5.8 ng/mL, respectively. ROC curve analysis revealed that the GH value at 30 minutes had the highest area under the curve.
CONCLUSION
The GH level of 5.7 ng/mL or higher at 30 minutes during OGTT could provide sufficient information to detect macroadenoma at the time of diagnosis.

Keyword

Acromegaly; Microadenoma; Macroadenoma; Growth hormone; Glucose tolerance test

MeSH Terms

Acromegaly*
Body Mass Index
Diagnosis
Discrimination (Psychology)
Glucose Tolerance Test
Growth Hormone*
Growth Hormone-Secreting Pituitary Adenoma
Humans
Hyperprolactinemia
Hypogonadism
Octreotide
Prevalence
Retrospective Studies
ROC Curve
Growth Hormone
Octreotide
Full Text Links
  • ENM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr